Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Allo-SCT using BU, CY and melphalan for children with AML in second CR.

Beier R, Albert MH, Bader P, Borkhardt A, Creutzig U, Eyrich M, Ehlert K, Gruhn B, Greil J, Handgretinger R, Holter W, Klingebiel T, Kremens B, Lang P, Mauz-Körholz C, Meisel R, Müller I, Peters C, Reinhardt D, Sedlacek P, Schulz A, Schuster FR, Schrauder A, Strahm B, Sykora KW, Wössmann W, Zimmermann M, Sauer MG.

Bone Marrow Transplant. 2013 May;48(5):651-6. doi: 10.1038/bmt.2012.204. Epub 2012 Oct 29.

PMID:
23103678
2.

Comparison of a fludarabine and melphalan combination-based reduced toxicity conditioning with myeloablative conditioning by radiation and/or busulfan in acute myeloid leukemia in Japanese children and adolescents.

Ishida H, Adachi S, Hasegawa D, Okamoto Y, Goto H, Inagaki J, Inoue M, Koh K, Yabe H, Kawa K, Kato K, Atsuta Y, Kudo K.

Pediatr Blood Cancer. 2015 May;62(5):883-9. doi: 10.1002/pbc.25389. Epub 2014 Dec 24.

PMID:
25545836
3.

[A comparison of toxicity and efficacy between busulfan plus fludarabine and busulfan plus cyclophosphamide for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia].

Liu H, Fan ZP, Jiang QL, Huang F, Zhou HS, Zhang X, Yu GP, Wu MQ, Sun J, Liu QF.

Zhonghua Nei Ke Za Zhi. 2012 Nov;51(11):880-4. Chinese.

PMID:
23291027
4.

Intravenous busulfan-cyclophosphamide as a preparative regimen before allogeneic hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia.

Tang W, Wang L, Zhao WL, Chen YB, Shen ZX, Hu J.

Biol Blood Marrow Transplant. 2011 Oct;17(10):1555-61. doi: 10.1016/j.bbmt.2011.04.003. Epub 2011 Apr 16.

5.

Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.

Saure C, Schroeder T, Zohren F, Groten A, Bruns I, Czibere A, Galonska L, Kondakci M, Weigelt C, Fenk R, Germing U, Haas R, Kobbe G.

Biol Blood Marrow Transplant. 2012 Mar;18(3):466-72. doi: 10.1016/j.bbmt.2011.09.006. Epub 2011 Sep 29.

6.

Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation.

Nagler A, Rocha V, Labopin M, Unal A, Ben Othman T, Campos A, Volin L, Poire X, Aljurf M, Masszi T, Socie G, Sengelov H, Michallet M, Passweg J, Veelken H, Yakoub-Agha I, Shimoni A, Mohty M.

J Clin Oncol. 2013 Oct 1;31(28):3549-56. doi: 10.1200/JCO.2013.48.8114. Epub 2013 Aug 26.

PMID:
23980086
7.

Successful outcome of allo-SCT in high-risk pediatric AML using chemotherapy-only conditioning and post transplant immunotherapy.

Bonanomi S, Connor P, Webb D, Ancliff P, Amrolia P, Rao K, McCloskey D, Hemmatpour S, Goulden N, Veys P.

Bone Marrow Transplant. 2008 Aug;42(4):253-7. doi: 10.1038/bmt.2008.160. Epub 2008 Jun 16. Erratum in: Bone Marrow Transplant. 2008 Nov;42(9):635. Bonnanomi, S [corrected to Bonanomi, S].

PMID:
18560412
8.

Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.

Mengarelli A, Iori A, Guglielmi C, Romano A, Cerretti R, Torromeo C, Micozzi A, Fenu S, Laurenti L, Donato V, De Felice L, Arcese W.

Haematologica. 2002 Jan;87(1):52-8.

9.

Allogeneic hematopoietic stem cell transplantation for pediatric patients with treatment-related myelodysplastic syndrome or acute myelogenous leukemia.

Kobos R, Steinherz PG, Kernan NA, Prockop SE, Scaradavou A, Small TN, Shukla N, Khalaf R, O'Reilly RJ, Boulad F.

Biol Blood Marrow Transplant. 2012 Mar;18(3):473-80. doi: 10.1016/j.bbmt.2011.11.009. Epub 2011 Nov 10.

10.

Hematopoietic stem cell transplantation for childhood myeloid malignancies after high-dose thiotepa, busulfan and cyclophosphamide.

Worth L, Tran H, Petropoulos D, Culbert S, Mullen C, Roberts W, Przepiorka D, Chan K.

Bone Marrow Transplant. 1999 Nov;24(9):947-52.

11.

Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients.

Kröger N, Zabelina T, Krüger W, Renges H, Stute N, Kabisch H, Jaburg N, Löliger C, Krüll A, Zander AR.

Bone Marrow Transplant. 2001 Feb;27(4):349-54.

12.

Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.

Kröger N, Zabelina T, Sonnenberg S, Krüger W, Renges H, Stute N, Finkenstein F, Mayer U, Holstein K, Fiedler W, Colberg H, Sonnen R, Kuse R, Braumann D, Metzner B, del Valle F, Erttmann R, Kabisch H, Zander AR.

Bone Marrow Transplant. 2000 Oct;26(7):711-6.

13.
14.

Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes.

Russell JA, Tran HT, Quinlan D, Chaudhry A, Duggan P, Brown C, Stewart D, Ruether JD, Morris D, Glick S, Gyonyor E, Andersson BS.

Biol Blood Marrow Transplant. 2002;8(9):468-76.

PMID:
12374451
15.

Long-term outcome of unrelated donor transplantation for AML using myeloablative conditioning incorporating pretransplant Alemtuzumab.

Das-Gupta EP, Russell NH, Shaw BE, Pearce RM, Byrne JL.

Biol Blood Marrow Transplant. 2007 Jun;13(6):724-33.

16.

Non-TBI hematopoietic stem cell transplantation in pediatric AML patients: a single-center experience.

Hamidieh AA, Alimoghaddam K, Jahani M, Bahar B, Mousavi SA, Iravani M, Behfar M, Jalali A, Jalili M, Hamdi A, Ghavamzadeh A.

J Pediatr Hematol Oncol. 2013 Aug;35(6):e239-45. doi: 10.1097/MPH.0b013e31827080fc. Erratum in: J Pediatr Hematol Oncol. 2014 Apr;36(3):252.

PMID:
23042019
17.

The outcome of children with acute myeloid leukemia (AML) post-allogeneic stem cell transplantation (SCT) is not improved by the addition of etoposide to the conditioning regimen.

Ayas M, Al-Seraihi A, Al-Mahr M, Al-Jefri A, Belgaumi A, Elhassan I, El-Solh H.

Pediatr Blood Cancer. 2006 Dec;47(7):926-30.

PMID:
16425264
18.

Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR.

Popat U, de Lima MJ, Saliba RM, Anderlini P, Andersson BS, Alousi AM, Hosing C, Nieto Y, Parmar S, Khouri IF, Kebriaei P, Qazilbash M, Champlin RE, Giralt SA.

Bone Marrow Transplant. 2012 Feb;47(2):212-6. doi: 10.1038/bmt.2011.61. Epub 2011 Mar 21.

19.

Early matched sibling hematopoietic cell transplantation for adult AML in first remission using an age-adapted strategy: long-term results of a prospective GOELAMS study.

Lioure B, Béné MC, Pigneux A, Huynh A, Chevallier P, Fegueux N, Blaise D, Witz B, Delain M, Cornillon J, Luquet I, Blanchet O, Cornillet-Lefebvre P, Carré M, Hunault M, Larosa F, Lamy T, Randriamalala E, Ojeda-Uribe M, Berthou C, Fornecker L, Harousseau JL, Bouscary D, Ifrah N, Cahn JY; GOELAMS.

Blood. 2012 Mar 22;119(12):2943-8. doi: 10.1182/blood-2011-05-352989. Epub 2012 Feb 9.

Supplemental Content

Support Center